About Peregrine Market Access

Pharmaceutical and biotechnology market access business solutions

Peregrine Market Access is a leading consulting, communications, and commercialization partner for the life sciences industry. We help our clients demonstrate the value of their FDA-approved treatments and therapies to the organizations that pay for them (health insurance providers and the government) so that sick people get the medicines they need.

Peregrine Market Access has been nationally recognized on the Inc. 5000 list of fastest-growing private companies in the United States (2022, 2021).

Why we exist
Demonstrating value is vital in the complex world of market access where payers are making decisions at a time of high prescription drug prices and limited budgets.

Biotechnology and pharmaceutical companies typically hire a number of consultants to help them do all of the things they need to be successful—one agency for healthcare policy consulting, one for data and market research, another for communications and creative execution, and on and on. Peregrine Market Access offers all of those capabilities in its group of healthcare companies.

Peregrine Market Access was created to be an all-encompassing partner. Our business is built on providing smart, compelling, and comprehensive market access services in the most efficient and effective way possible. Our sights are set on redefining the value of healthcare in America and our success demonstrates just how determined we are.

What’s in a name?
Peregrine Market Access is a veteran-owned small business founded by market access expert John Guarino in 2016. Early in his career, John served in the US Army as a paratrooper in the 82nd Airborne Division. The second brigade of that division is nicknamed the “Falcon brigade,” which inspired the naming of Peregrine Market Access.

Beyond the name, John has leveraged the Army ethos of being in service to others to passionately help patients receive the medicine and treatments they need and give back to causes we believe in.